Association of Remdesivir Treatment With Survival, Length of Hospital Stay Among US Veterans Hospitalized With COVID-19

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 15, 2021

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2021.14741?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=071521

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

What The Study Did: In this observational study using data from the Veterans Health Administration for 2,344 U.S. veterans hospitalized with COVID-19, remdesivir treatment was associated with prolonged hospitalization but wasn’t associated with improved survival.

Authors: Michael E. Ohl, M.D., M.S.P.H., of the Carver College of Medicine at the University of Iowa in Iowa City, is the corresponding author.

 

(doi:10.1001/jamanetworkopen.2021.14741)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.